Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetramethylpyrazine nitrone + placebo
- Development stage
- Unknown
- Lead developer
- Guangzhou Magpie Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Tetramethylpyrazine nitrone + placebo refers to the combination of the investigational drug tetramethylpyrazine nitrone (TBN) and a matching inactive comparator (placebo), as used in randomized controlled clinical trials. Tetramethylpyrazine nitrone is a synthetic derivative of tetramethylpyrazine (TMP), designed to enhance antioxidant and neuroprotective properties by incorporating a powerful free radical scavenging nitrone moiety. TBN acts through multiple mechanisms including brain-derived neurotrophic factor agonism, calcium channel antagonism, cyclic AMP response element-binding protein stimulation, free radical scavenging, mTOR inhibition, and proto-oncogene protein c-akt modulation. It is being developed primarily for neurological and vascular disorders such as ischemic stroke, amyotrophic lateral sclerosis (ALS), diabetic nephropathy, and potentially Alzheimer's disease. The combination with placebo is standard in clinical research to assess efficacy and safety compared to no active treatment[2][7][9].
- Other names
- tetramethylpyrazine nitrone + placebo
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)NTRK2 (Tropomyosin-related kinase receptor type B)CaV (Voltage-gated calcium channel protein complex)
Beyond the preview
Go deeper on tetramethylpyrazine nitrone + placebo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetramethylpyrazine nitrone + placebo.